Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FOLDNASDAQ:HALONASDAQ:MDGLNASDAQ:RGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFOLDAmicus Therapeutics$6.10-2.2%$6.93$5.81▼$12.65$1.88B0.642.85 million shs5.50 million shsHALOHalozyme Therapeutics$54.43+0.0%$59.27$42.01▼$70.51$6.71B1.261.62 million shs1.87 million shsMDGLMadrigal Pharmaceuticals$270.87-0.3%$308.27$200.63▼$377.46$6.01B-0.91379,631 shs191,613 shsRGENRepligen$121.18-1.1%$129.03$102.97▼$182.52$6.81B1.21739,589 shs515,449 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFOLDAmicus Therapeutics-2.24%-3.79%-17.46%-33.62%-36.33%HALOHalozyme Therapeutics+0.02%+0.93%-10.14%-5.67%+26.35%MDGLMadrigal Pharmaceuticals-0.26%-2.30%-18.24%-19.32%+21.31%RGENRepligen-1.11%+0.81%-15.63%-22.59%-22.69%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFOLDAmicus Therapeutics4.0393 of 5 stars3.41.00.04.33.70.01.9HALOHalozyme Therapeutics4.8096 of 5 stars3.11.00.04.43.42.54.4MDGLMadrigal Pharmaceuticals4.2262 of 5 stars3.51.00.04.62.64.20.6RGENRepligen4.9013 of 5 stars4.32.00.04.54.03.31.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFOLDAmicus Therapeutics 2.70Moderate Buy$16.22165.94% UpsideHALOHalozyme Therapeutics 2.17Hold$61.9013.72% UpsideMDGLMadrigal Pharmaceuticals 2.90Moderate Buy$416.3353.70% UpsideRGENRepligen 2.64Moderate Buy$173.2542.97% UpsideCurrent Analyst Ratings BreakdownLatest FOLD, HALO, RGEN, and MDGL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025HALOHalozyme TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$73.00 ➝ $62.005/13/2025HALOHalozyme TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/13/2025HALOHalozyme TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeMarket Perform ➝ Underperform$47.005/7/2025HALOHalozyme TherapeuticsBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/7/2025HALOHalozyme TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$60.00 ➝ $65.005/5/2025RGENRepligenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$180.00 ➝ $180.005/2/2025FOLDAmicus TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$21.00 ➝ $22.005/2/2025FOLDAmicus TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$12.00 ➝ $9.005/2/2025MDGLMadrigal PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$441.00 ➝ $458.005/2/2025MDGLMadrigal PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$422.00 ➝ $460.005/2/2025MDGLMadrigal PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$394.00 ➝ $420.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFOLDAmicus Therapeutics$543.14M3.46N/AN/A$0.63 per share9.68HALOHalozyme Therapeutics$1.08B6.19$4.41 per share12.35$2.95 per share18.45MDGLMadrigal Pharmaceuticals$317.38M18.95N/AN/A$20.53 per share13.19RGENRepligen$650.43M10.47$2.26 per share53.61$35.19 per share3.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFOLDAmicus Therapeutics-$151.58M-$0.09N/A14.191.51-10.62%12.44%2.60%8/14/2025 (Estimated)HALOHalozyme Therapeutics$281.59M$3.7615.878.750.4243.74%157.78%25.34%8/5/2025 (Estimated)MDGLMadrigal Pharmaceuticals-$373.63M-$18.05N/AN/AN/AN/A-71.78%-53.25%8/6/2025 (Estimated)RGENRepligen$35.60M-$0.45N/A51.354.54-4.64%4.21%2.94%7/29/2025 (Estimated)Latest FOLD, HALO, RGEN, and MDGL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025HALOHalozyme Therapeutics$0.98$1.11+$0.13$0.93$231.21 million$264.86 million5/1/2025Q1 2025MDGLMadrigal Pharmaceuticals-$3.62-$3.32+$0.30-$3.32$112.79 million$137.25 million4/29/2025Q1 2025RGENRepligen$0.35$0.39+$0.04$0.10$163.65 million$169.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFOLDAmicus TherapeuticsN/AN/AN/AN/AN/AHALOHalozyme TherapeuticsN/AN/AN/AN/AN/AMDGLMadrigal PharmaceuticalsN/AN/AN/AN/AN/ARGENRepligenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFOLDAmicus Therapeutics2.013.392.42HALOHalozyme Therapeutics4.147.809.15MDGLMadrigal Pharmaceuticals0.155.985.93RGENRepligen0.2610.448.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFOLDAmicus TherapeuticsN/AHALOHalozyme Therapeutics97.79%MDGLMadrigal Pharmaceuticals98.50%RGENRepligen97.64%Insider OwnershipCompanyInsider OwnershipFOLDAmicus Therapeutics2.20%HALOHalozyme Therapeutics2.90%MDGLMadrigal Pharmaceuticals21.50%RGENRepligen1.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFOLDAmicus Therapeutics480307.93 million292.23 millionOptionableHALOHalozyme Therapeutics390123.22 million120.20 millionOptionableMDGLMadrigal Pharmaceuticals9022.20 million16.84 millionOptionableRGENRepligen2,02056.18 million55.36 millionOptionableFOLD, HALO, RGEN, and MDGL HeadlinesRecent News About These CompaniesRepligen Co. (NASDAQ:RGEN) Position Raised by Polar Asset Management Partners Inc.May 29 at 5:14 AM | marketbeat.comTidal Investments LLC Decreases Position in Repligen Co. (NASDAQ:RGEN)May 29 at 3:57 AM | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $33.88 Million Stock Position in Repligen Co. (NASDAQ:RGEN)May 28 at 4:48 AM | marketbeat.comRepligen Announces Publication of the Company’s 2024 Corporate Sustainability ReportMay 27 at 10:20 AM | finance.yahoo.comRepligen Announces Publication of the Company's 2024 Corporate Sustainability ReportMay 27 at 8:00 AM | investing.comRepligen Announces Publication of the Company's 2024 Corporate Sustainability ReportMay 27 at 7:30 AM | globenewswire.comRepligen Co. (NASDAQ:RGEN) Shares Bought by Two Sigma Advisers LPMay 24, 2025 | marketbeat.comRepligen Co. (NASDAQ:RGEN) Shares Sold by AWM Investment Company Inc.May 23, 2025 | marketbeat.comTeza Capital Management LLC Sells 10,705 Shares of Repligen Co. (NASDAQ:RGEN)May 23, 2025 | marketbeat.comRepligen Corporation to Present at William Blair Growth ConferenceMay 22, 2025 | uk.finance.yahoo.comTwo Sigma Investments LP Lowers Stake in Repligen Co. (NASDAQ:RGEN)May 22, 2025 | marketbeat.comPoint72 Asia Singapore Pte. Ltd. Trims Stock Position in Repligen Co. (NASDAQ:RGEN)May 22, 2025 | marketbeat.comNuveen Asset Management LLC Decreases Stock Position in Repligen Co. (NASDAQ:RGEN)May 22, 2025 | marketbeat.comPolar Asset Management Partners Inc. Buys 3,000 Shares of Repligen Co. (NASDAQ:RGEN)May 20, 2025 | marketbeat.comGotham Asset Management LLC Has $965,000 Stake in Repligen Co. (NASDAQ:RGEN)May 20, 2025 | marketbeat.comRepligen Co. (NASDAQ:RGEN) Receives $173.25 Average Price Target from AnalystsMay 20, 2025 | americanbankingnews.comRepligen Co. (NASDAQ:RGEN) Given Average Recommendation of "Moderate Buy" by AnalystsMay 19, 2025 | marketbeat.comBank of America Corp DE Trims Holdings in Repligen Co. (NASDAQ:RGEN)May 18, 2025 | marketbeat.comPoint72 Asset Management L.P. Has $132.23 Million Stake in Repligen Co. (NASDAQ:RGEN)May 17, 2025 | marketbeat.comInsider Sell: Anthony Hunt Sells 26,447 Shares of Repligen Corp (RGEN)May 17, 2025 | gurufocus.comRepligen Holds Annual Shareholders Meeting, Key Decisions MadeMay 15, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookQualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumMeta's Institutional & Insider Data Fuels Bulls Despite DisparityBy Leo Miller | May 28, 2025View Meta's Institutional & Insider Data Fuels Bulls Despite DisparityFOLD, HALO, RGEN, and MDGL Company DescriptionsAmicus Therapeutics NASDAQ:FOLD$6.10 -0.14 (-2.24%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$6.10 0.00 (-0.08%) As of 04:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.Halozyme Therapeutics NASDAQ:HALO$54.43 +0.01 (+0.02%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$55.26 +0.83 (+1.52%) As of 06:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.Madrigal Pharmaceuticals NASDAQ:MDGL$270.87 -0.70 (-0.26%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$270.50 -0.37 (-0.14%) As of 06:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.Repligen NASDAQ:RGEN$121.18 -1.36 (-1.11%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$121.06 -0.12 (-0.10%) As of 05/28/2025 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
